Supplements and Compounds Library
Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 145–168 of 328
Novos trial shows cardiovascular benefits in aging adults
A Novos clinical trial demonstrated statistically significant reductions in systolic and diastolic blood pressure, improved lipid profiles, and favorable shifts in metabolic markers among adults over 40 following the company's integrated lifestyle and metabolic support program. These findings support multimodal intervention as an approach to reducing established cardiovascular risk factors associated with aging.
Cognition Therapeutics reports Zervimesine slows NPI decline in DLB
Zervimesine (CT1812) demonstrated an 86% slowing of neuropsychiatric symptom decline in dementia with Lewy bodies patients compared to placebo in Phase 2 testing. This result supports advancement to late-stage trials and suggests a potential disease-modifying mechanism for a condition with limited therapeutic options.
Immune Tolerance Induction Unlocks Allogeneic Islet Therapy
LyGenesis received funding to develop immune tolerance protocols for pancreatic islet transplantation in type 1 diabetes, leveraging thymic biology to enable allogeneic cell therapy without chronic immunosuppression. This approach addresses a critical barrier in cellular regenerative medicine: preventing immune rejection while restoring endocrine function.
Stealth reports FORZINITY launch momentum and pipeline progress
Stealth reports 33 patients initiated on FORZINITY (elamipretide) for Barth syndrome with 85% coverage and 100% enrollment in patient support programs. The company is pursuing label expansion for younger patients and advancing a pipeline targeting mitochondrial dysfunction across multiple tissues.
C15 Fatty Acid Challenges Saturated Fat Dogma in Aging
Pentadecanoic acid (C15:0), an odd-chain saturated fatty acid, demonstrates cellular and systemic effects that distinguish it from traditional saturated fats implicated in poor health outcomes. This finding challenges decades of undifferentiated dietary guidance against saturated fat and suggests nutritional recommendations require greater molecular specificity to align with emerging evidence on healthy aging.
ImmunoBrain presents Phase 1b data for immune checkpoint therapy
ImmunoBrain's anti-PD-L1 therapy (IBC-Ab002) demonstrated acceptable safety and tolerability in early Alzheimer's patients, with cerebrospinal fluid biomarkers suggesting potential protection against synaptic and neuronal decline. This represents a shift toward immune-based approaches for neurodegenerative disease, targeting the chronic immune suppression that characterizes aging.
Blarcamesine links functional and cognitive outcomes in AD-004 trial
Blarcamesine demonstrated a measurable correlation between MRI-detected preservation of brain volume and slowing of cognitive decline in early Alzheimer's disease, with particularly strong outcomes in a genetically defined subpopulation. Long-term data suggest a potential delay in functional deterioration of approximately 18 months over 33 months of treatment.
ACSS2 is essential for myelination via maintenance of the OPC population
ACSS2, an enzyme that regulates histone acetylation, maintains the oligodendrocyte precursor cell pool essential for myelin formation. Acetate supplementation restores myelination capacity after aging or injury, suggesting a metabolic lever for preserving neural insulation and signal transmission across the lifespan.
Higher tyrosine levels may trim years off life
A UK Biobank study of 272,500 participants links elevated blood tyrosine levels to reduced lifespan, with a stronger effect in men (approximately one year lost per standard deviation increase). Using Mendelian randomization to establish causality rather than mere association, the research suggests tyrosine acts as a causal factor in mortality risk, independent of phenylalanine.
#384 – Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer’s prevention
Obicetrapib, a CETP inhibitor, demonstrates cardiovascular benefits and potential neuroprotective effects against Alzheimer's disease—outcomes that distinguish it from four previous compounds in this drug class. The mechanism addresses both systemic lipid metabolism and cerebral amyloid pathology, making it relevant to multi-system longevity strategies.
Lilly races to become first longevity Big Pharma
Eli Lilly's $2.75 billion partnership with Insilico Medicine represents a strategic pivot toward AI-driven drug discovery aimed at aging-related pathology beyond current GLP-1 applications. The deal signals that large pharmaceutical companies now view longevity therapeutics as a commercially serious category worthy of substantial investment in discovery infrastructure.
Cognito lands $105m for sensory stimulation Alzheimer’s therapy
Cognito Therapeutics raised $105 million to advance Spectris, a non-invasive device delivering synchronized visual and auditory stimulation designed to restore disrupted neural oscillations in Alzheimer's disease. Prior feasibility data showed slowed cognitive decline and 69% reduction in brain volume loss, with a 673-participant pivotal trial now fully enrolled and expected to yield results that could support regulatory submission in 2027.
NeuroSense reports significant survival benefit with PrimeC in ALS trial
PrimeC, a combination of two FDA-approved drugs in extended-release formulation, demonstrated a 14.7-month median survival improvement in ALS patients (36.3 months versus 21.4 months with placebo), with a 65% reduction in mortality risk after adjustment for baseline factors. This represents a clinically meaningful survival benefit in a neurodegenerative disease with limited therapeutic options.
AI-Designed TNIK Inhibitor Targets Aging in Pulmonary Fibrosis
Insilico Medicine's rentosertib, an AI-designed TNIK inhibitor discovered through aging-biology-informed target identification, has advanced to Phase III trials for idiopathic pulmonary fibrosis. The program demonstrates that computational drug discovery combined with geroscience principles can identify therapeutically relevant targets overlooked by conventional approaches.
Oligomer-selective antibody PMN310 demonstrates sustained CSF reduction
ProMIS demonstrated dose-dependent reduction of amyloid-beta oligomers in cerebrospinal fluid following a single dose of PMN310 in Phase 1a testing, with good tolerability and a 27-day CSF half-life supporting longer dosing intervals. A Phase 1b trial enrolling 144 participants is underway, with interim data expected in coming weeks and full results by early 2027.
Niagen Bioscience reports 30% sales growth in 2025
Niagen Bioscience reported 30% year-over-year sales growth to $129.4 million in 2025, with net income more than doubling and gross margins expanding 250 basis points. The growth was driven by increased Tru Niagen product sales and ingredient revenue, supported by e-commerce expansion and market penetration.
GSK acquires 35Pharma in $950m deal, advancing PH drug
GSK acquired Montreal-based 35Pharma for $950 million, gaining HS235, a targeted pulmonary hypertension candidate that addresses vascular dysfunction while showing early signals of metabolic benefit—fat-selective weight loss, preserved muscle, and improved insulin sensitivity. The drug represents a shift toward precision mechanisms that reduce side-effect burden in chronic disease management.
Maze Therapeutics reports positive phase 2 data for MZE829
MZE829, an APOL1 inhibitor, demonstrated a 35.6% mean reduction in urinary albumin excretion at 12 weeks in APOL1-mediated kidney disease, with substantially larger reductions in focal segmental glomerulosclerosis (61.8%) and non-diabetic AMKD (48.6%). The compound was well tolerated with no serious adverse events, positioning it as a potential therapeutic for progressive kidney disease across multiple etiologies.
Zervimesine patent strengthens neurodegeneration drug pipeline
Cognition Therapeutics secured a 20-year US patent for a polymorphic crystalline formulation of Zervimesine (CT1812), a lead candidate targeting Alzheimer's disease, dementia with Lewy bodies, and geographic atrophy. The patent protection extends through 2045, with potential extension to 2050, covering composition, manufacturing process, and therapeutic applications for age-related neurodegeneration.
4Moving Biotech granted FDA fast track for 4P004
The FDA granted Fast Track Designation to 4P004, a GLP-1 analog designed for direct injection into the knee joint to treat osteoarthritis with inflammation in patients who have failed two prior drug therapies. The designation accelerates regulatory review for a candidate positioned as the first disease-modifying treatment targeting underlying joint degradation rather than symptoms alone.
Endlyz raises Seed 2 financing, leans into root-cause neuroscience
Endlyz Therapeutics is pursuing disease modification in Parkinson's by targeting lysosomal dysfunction at the cellular level, addressing the root cause of neurodegeneration rather than managing symptoms. This approach represents a shift toward interventions that could slow disease progression before irreversible damage accumulates.
Aerska lands $39m to advance genetic medicines to the brain
Aerska has secured $39 million in Series A funding to advance RNA interference therapies that cross the blood-brain barrier for neurodegenerative diseases including Alzheimer's and Parkinson's. The company's platform addresses a critical delivery bottleneck that has limited genetic medicine effectiveness in the central nervous system.
AMX0114 Tolerability Supports ALS Neuroprotection Strategy
Amylyx's AMX0114 demonstrated safety in early-stage ALS trials with no drug-related serious adverse events at the lowest dose level, supporting progression to higher doses. Biomarker stability suggests the compound may interrupt pathological neuronal processes without triggering acute toxicity.
ProMIS Neurosciences details new ALS and Parkinson’s data
ProMIS Neurosciences presented preclinical vaccine data targeting misfolded proteins in ALS, Parkinson's, and Alzheimer's disease. The approach uses computational epitope selection to generate selective immune responses against pathogenic protein conformations implicated in neurodegeneration.